Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a 0.5 mg lyophilized kit for intravenous use. It forms a technetium‑99m complex that localises in myocardial cells in proportion to blood flow, allowing single‑photon emission computed tomography (SPECT) to evaluate coronary artery disease, myocardial viability, and stress‑induced perfusion changes in adult patients.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide through robust quality systems.

Myoview (technetium‑99m tetrofosmin) is used in cardiac imaging to assess myocardial perfusion.

- Coronary artery disease detection: Provides SPECT images of myocardial perfusion to identify obstructive lesions. - Myocardial viability assessment: Differentiates viable from non‑viable myocardium after infarction. - Stress‑test perfusion evaluation: Visualises blood flow changes during pharmacologic or exercise stress testing.

Adverse reactions may occur following intravenous administration of Myoview.

Common Side Effects: - Nausea: Mild to moderate feeling of stomach upset. - Headache: Transient discomfort often resolving without intervention. - Injection site pain: Local discomfort at the venipuncture site. - Flushing: Warm sensation and reddening of the skin. - Dizziness: Temporary light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: Severe allergic response requiring immediate medical attention. - Hypotension: Marked drop in blood pressure that may cause fainting. - Cardiac arrhythmia: Abnormal heart rhythm potentially leading to hemodynamic compromise. - Myocardial infarction: Rare occurrence of heart attack following administration. - Radiation‑induced skin injury: Localized skin changes at the injection site.

Myoview should be used with consideration of patient‑specific factors and handling requirements. - Pregnancy: Use only if the potential diagnostic benefit outweighs unknown fetal risk. - Breastfeeding: Discontinue nursing or withhold the drug until sufficient time has passed for clearance. - Renal impairment: Monitor patients with reduced kidney function as clearance may be altered. - Thyroid disorders: Caution in patients with hyperthyroidism due to possible iodine uptake interference. - Concomitant radiopharmaceuticals: Avoid simultaneous use of other technetium‑99m agents to prevent labeling competition. - Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Myoview may interact with other agents that affect radiotracer distribution or cardiac physiology.

Major Interactions (Avoid): - Concurrent technetium‑99m labeled agents: Can compete for labeling and reduce image quality. - High‑dose iodine contrast within 24 h: May interfere with myocardial uptake of the tracer.

Moderate Interactions (Monitor Closely): - Beta‑blockers: May blunt heart rate response during stress testing. - Calcium channel blockers: Can alter myocardial blood flow and affect perfusion images. - Thyroid hormone therapy: May influence radiotracer distribution in thyroid tissue.